CNSY CERENOME, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1095981 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-32.9%
TTM net income YoY-47.4%
TTM EPS YoY143.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-832.6%
Net margin-859.5%
FCF margin-813.5%
EBITDA margin-817.7%
Returns
ROE-1,468.0%
ROA-196.4%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets107.6%
Debt / equity—
Current ratio0.61x
Interest coverage-815.92x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue39.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $722,000 | $411,000 | $1.03M | $1.37M | $1.40M | $1.39M | $1.06M | $1.41M |
| R&D expense | $2.11M | $4.26M | $2.87M | $2.94M | $2.44M | $1.25M | $1.76M | $2.19M |
| SG&A expense | $5.16M | $5.20M | $5.28M | $4.17M | $3.44M | $1.68M | $2.84M | $3.13M |
| Operating income | -$7.46M | -$9.06M | -$7.12M | -$5.74M | -$4.48M | -$1.54M | -$3.54M | -$3.90M |
| Interest expense | $14,000 | $5,000 | $17,000 | $0 | $0 | $0 | $548,000 | $57,000 |
| Net income | -$8.66M | -$9.01M | -$6.95M | -$5.71M | -$4.42M | $5.15M | -$17.40M | -$3.90M |
| EBITDA | -$7.31M | -$8.92M | -$7.02M | -$5.60M | -$4.41M | -$1.46M | -$3.39M | -$3.70M |
| EPS (basic) | -1.14 | -1.31 | -1.05 | — | -1.03 | 0.62 | -29.86 | — |
| EPS (diluted) | -1.14 | -1.31 | -1.05 | — | -1.03 | -0.16 | -29.86 | — |
| Weighted avg. shares (diluted) | 7.57M | 6.90M | 6.65M | — | 4.30M | 8.37M | 582,668 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $879,000 | $2.37M | $3.02M | $4.26M | $13.29M | $2.23M | $9.87M | $76,000 |
| Short-term investments | $3.99M | $6.22M | $12.09M | $4.36M | $3.31M | $4.65M | — | $3.53M |
| Receivables | $722,000 | — | — | — | — | — | — | — |
| Inventory | $235,000 | — | — | — | — | — | — | — |
| Current assets | $8.07M | $11.77M | $18.03M | $14.85M | $17.59M | $9.21M | $10.87M | $5.26M |
| PP&E, net | $1.35M | $1.41M | $1.01M | $257,000 | $273,000 | $289,000 | $324,000 | $448,000 |
| Goodwill | $372,000 | $372,000 | $372,000 | $372,000 | $372,000 | $372,000 | $372,000 | $372,000 |
| Intangibles | — | — | — | $333,000 | — | — | — | $469,000 |
| Total assets | $12.20M | $14.03M | $19.92M | $16.32M | $18.67M | $10.35M | $12.06M | $6.63M |
| Current liabilities | $13.12M | $8.57M | $7.96M | $12.31M | $13.62M | $7.32M | $10.56M | $15.55M |
| Total liabilities | $13.12M | $8.57M | $7.96M | $12.33M | $13.62M | $7.32M | $35.70M | $15.58M |
| Shareholders' equity | -$923,000 | $5.46M | $11.96M | $4.00M | $5.05M | $3.03M | -$23.64M | -$8.95M |
| Shares outstanding | 7.88M | 7.31M | 6.86M | 5.55M | 131.61M | 92.18M | 17.00M | 5.90M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.67M | -$7.13M | -$6.24M | -$6.26M | -$2.55M | -$5.80M | -$6.17M | -$1.21M |
| Capital expenditure | $51,000 | $499,000 | $818,000 | $30,000 | $27,000 | $7,000 | $3,000 | $11,000 |
| Free cash flow | -$7.72M | -$7.63M | -$7.06M | -$6.29M | -$2.58M | -$5.80M | -$6.17M | -$1.22M |
| Investing cash flow | $2.00M | $5.37M | -$8.53M | -$1.08M | $1.30M | -$4.63M | $3.56M | $64,000 |
| Financing cash flow | $4.18M | $1.11M | $9.04M | $2.80M | $12.31M | $2.80M | $12.40M | $0 |
| Depreciation & amortization | $145,000 | $137,000 | $96,000 | $145,000 | $77,000 | $77,000 | $146,000 | $199,000 |
| Stock-based compensation | $709,000 | $830,000 | $1.02M | $713,000 | $527,000 | $152,000 | $148,000 | $128,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.